charts look very bulish.
Great buy for an easy double.
ZYNE which is located in Pennsylvania, also is studying a CBD drug for epilepsy. The companyas ZYN002 is a synthetic that mimics the effects of natural cannabinoids and is administered through the skin via gel. ZYNE's transdermal system might provide better drug exposure than GWPas Epidiolex, according to Biren Amin, an equity analyst at Jefferies, who set a price target for Zynerba of $32 in a mid-March note, according to Forbes
unless CELG gets them at $20+
We ended the year with approximately $9.6 million in cash and equivalents. We expect our cash burn to decrease significantly in the second quarter of 2016 to approximately $2.5 million. Further decreases over the balance of the year should result in our current cash balances being sufficient to fund operations for the next 12 months. We believe that this is sufficient time to demonstrate a long-term growth potential of our On-Net platform.
See you at $30+